GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (FRA:2GH) » Definitions » Cyclically Adjusted PS Ratio

Merus NV (FRA:2GH) Cyclically Adjusted PS Ratio : 51.91 (As of Jun. 10, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Merus NV Cyclically Adjusted PS Ratio?

As of today (2024-06-10), Merus NV's current share price is €48.80. Merus NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.94. Merus NV's Cyclically Adjusted PS Ratio for today is 51.91.

The historical rank and industry rank for Merus NV's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:2GH' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 26.91   Med: 42.17   Max: 56.59
Current: 49.91

During the past years, Merus NV's highest Cyclically Adjusted PS Ratio was 56.59. The lowest was 26.91. And the median was 42.17.

FRA:2GH's Cyclically Adjusted PS Ratio is ranked worse than
92.63% of 502 companies
in the Biotechnology industry
Industry Median: 5.43 vs FRA:2GH: 49.91

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merus NV's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.125. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.94 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merus NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Merus NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Cyclically Adjusted PS Ratio Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 26.05

Merus NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 26.05 42.49

Competitive Comparison of Merus NV's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Merus NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merus NV's Cyclically Adjusted PS Ratio falls into.



Merus NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Merus NV's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=48.80/0.94
=51.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merus NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Merus NV's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.125/128.5800*128.5800
=0.125

Current CPI (Mar. 2024) = 128.5800.

Merus NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.240 0.000
201409 0.020 99.960 0.026
201412 0.025 99.050 0.032
201503 0.004 99.750 0.005
201506 0.072 100.230 0.092
201509 0.006 100.500 0.008
201512 0.001 99.730 0.001
201603 0.004 100.310 0.005
201606 0.016 100.260 0.021
201609 0.055 100.570 0.070
201612 -0.006 100.710 -0.008
201703 0.207 101.440 0.262
201706 0.286 101.370 0.363
201709 0.289 102.030 0.364
201712 0.316 101.970 0.398
201803 0.469 102.470 0.589
201806 0.281 103.100 0.350
201809 0.285 103.950 0.353
201812 0.458 103.970 0.566
201903 0.334 105.370 0.408
201906 0.241 105.840 0.293
201909 0.316 106.700 0.381
201912 0.263 106.800 0.317
202003 0.197 106.850 0.237
202006 0.185 107.510 0.221
202009 0.250 107.880 0.298
202012 0.247 107.850 0.294
202103 0.194 108.870 0.229
202106 0.268 109.670 0.314
202109 0.302 110.790 0.350
202112 0.314 114.010 0.354
202203 0.243 119.460 0.262
202206 0.275 119.050 0.297
202209 0.144 126.890 0.146
202212 0.217 124.940 0.223
202303 0.272 124.720 0.280
202306 0.200 125.830 0.204
202309 0.192 127.160 0.194
202312 0.142 126.450 0.144
202403 0.125 128.580 0.125

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merus NV  (FRA:2GH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Merus NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Merus NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (FRA:2GH) Business Description

Industry
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV (FRA:2GH) Headlines

No Headlines